Pharmaceutical companies that have, until recently, eschewed cloud computing are migrating applications into that environment. Adoption began gradually, first with functions that aren’t mission-critical. After a few years’ experience, they’re still cautious, seeking to adopt the cloud strategically while minimizing risks.
Inviting FDA scientists into your manufacturing facility or laboratory for one or two days may feel unsettling, but it can be rewarding when the visits are designed to bring FDA scientists up to speed on real-world issues and new technologies.
Two American organizations go on the record to discuss their work with Cuban researchers and their efforts to bring innovative research involving cancer vaccines and levels of consciousness (e.g., comas, brain death) to American patients.
The need for discussions regarding guidelines for the development of therapeutics made from human cells, tissues, and cell- and tissue-based products has been building for a long time.
The fascinating stories of how Akari Therapeutics and Oncolytics Biotech each faced devastating challenges in their evolution and ultimately reinvented themselves.
Top-performing pharmaceutical companies aren’t like their peers. The top six companies have each found their own “secret sauce” that, according to a recent Accenture report, helps them dominate their markets and boost profit margins far beyond those of their peers.
Life sciences companies are at a crossroads, although they may not recognize it. Information technology is transitioning from a tool to a strategic element that contributes to business success. Most boards, however, are ill-equipped to guide this transformation.
"Companies that recognize the opportunities associated with digital transformation are more likely to bring in fresh blood,” Murray Aitken, executive director, IMS Institute, says.
According to “The Patient is IN: Pharma’s Growing Opportunity in Patient Services,” a recent Accenture survey of 200 patient services executives in the U.S. and Europe, 9 of the 10 most common patient services deliver above-average business impact.
DelMar Pharmaceuticals’ small molecule oncology program began with a short list of compounds that advanced to Phase 2 at the NIH but were never commercialized. By developing drugs that were in Phase 2 trials many years ago rather than creating entirely new drugs, DelMar has the benefit of beginning a program with a large body of knowledge.
